The Future of Preclinical Animal Models in Pharmaceutical Discovery and Development A Need to Bring In Cerebro to the In Vivo Discussions

作者: Jeffrey I. Everitt

DOI: 10.1177/0192623314555162

关键词:

摘要: Animal models have provided an important tool to help make the decision take potential therapies from preclinical studies humans. In past several years, strong reliance of pharmaceutical discovery and development process on use animal has come under increasing scrutiny for ethical scientific reasons. Several prominent widely publicized articles reported limited concordance experiments with subsequent human clinical trials. Recent assessments quality suggested that this translational failure may be due in part shortcomings planning, conduct, reporting vivo studies. This article will emphasize methods assure best practice rigor study reporting. It introduce so-called 3Rs relevance, robustness, reproducibility approach review new trends research communities.

参考文章(56)
David Stout, Stuart S. Berr, Amy LeBlanc, Joseph D. Kalen, Dustin Osborne, Julie Price, Wynne Schiffer, Claudia Kuntner, Jonathan Wall, Guidance for methods descriptions used in preclinical imaging papers. Molecular Imaging. ,vol. 12, pp. 1- 15 ,(2013) , 10.2310/7290.2013.00055
Carlijn R Hooijmans, Rob de Vries, Marlies Leenaars, Jo Curfs, Merel Ritskes-Hoitinga, Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines British Journal of Pharmacology. ,vol. 162, pp. 1259- 1260 ,(2011) , 10.1111/J.1476-5381.2010.01128.X
Michael Emerson, Refinement, reduction and replacement approaches to in vivo cardiovascular research British Journal of Pharmacology. ,vol. 161, pp. 749- 754 ,(2010) , 10.1111/J.1476-5381.2010.00959.X
Pandora Pound, Shah Ebrahim, Peter Sandercock, Michael B Bracken, Ian Roberts, Where is the evidence that animal research benefits humans BMJ. ,vol. 328, pp. 514- 517 ,(2004) , 10.1136/BMJ.328.7438.514
Marcin F. Osuchowski, Daniel G. Remick, James A. Lederer, Charles H. Lang, Ansgar O. Aasen, Mayuki Aibiki, Luciano C. Azevedo, Soheyl Bahrami, Mihaly Boros, Robert Cooney, Salvatore Cuzzocrea, Yong Jiang, Wolfgang G. Junger, Hiroyuki Hirasawa, Richard S. Hotchkiss, Xiang-An Li, Peter Radermacher, Heinz Redl, Reinaldo Salomao, Amin Soebandrio, Christoph Thiemermann, Jean-Louis Vincent, Peter Ward, Yong-Ming Yao, Huang-Ping Yu, Basilia Zingarelli, Irshad H. Chaudry, Abandon the mouse research ship? Not just yet! Shock. ,vol. 41, pp. 463- 475 ,(2014) , 10.1097/SHK.0000000000000153
Valerie C. Henderson, Jonathan Kimmelman, Dean Fergusson, Jeremy M. Grimshaw, Dan G. Hackam, Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments PLoS Medicine. ,vol. 10, pp. e1001489- ,(2013) , 10.1371/JOURNAL.PMED.1001489
C. Glenn Begley, Reproducibility: Six red flags for suspect work Nature. ,vol. 497, pp. 433- 434 ,(2013) , 10.1038/497433A
C. Glenn Begley, Lee M. Ellis, Drug development: Raise standards for preclinical cancer research Nature. ,vol. 483, pp. 531- 533 ,(2012) , 10.1038/483531A
John P. Sundberg, Derry C. Roopenian, Edison T. Liu, Paul N. Schofield, The Cinderella Effect: Searching for the Best Fit between Mouse Models and Human Diseases Journal of Investigative Dermatology. ,vol. 133, pp. 2509- 2513 ,(2013) , 10.1038/JID.2013.238